CN118526444A - Ketoprofen gel and preparation method thereof - Google Patents
Ketoprofen gel and preparation method thereof Download PDFInfo
- Publication number
- CN118526444A CN118526444A CN202410445904.9A CN202410445904A CN118526444A CN 118526444 A CN118526444 A CN 118526444A CN 202410445904 A CN202410445904 A CN 202410445904A CN 118526444 A CN118526444 A CN 118526444A
- Authority
- CN
- China
- Prior art keywords
- ketoprofen
- weight
- parts
- gel
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于药物制剂技术领域,具体涉及一种酮洛芬凝胶剂及其制备方法。本发明酮洛芬凝胶剂由酮洛芬、西黄蓍胶、硫代甘油、L‑苯丙氨酸、丙三醇三乙酸酯、乙醇、抑菌剂、水组成。通过优化处方、改进制备工艺,提升了其透皮效果好、且对皮肤刺激性小,还显著提升了酮洛芬凝胶的保湿性能和含量稳定性。
The present invention belongs to the technical field of pharmaceutical preparations, and in particular to a ketoprofen gel and a preparation method thereof. The ketoprofen gel of the present invention is composed of ketoprofen, tragacanth gum, thioglycerol, L-phenylalanine, glycerol triacetate, ethanol, an antibacterial agent, and water. By optimizing the prescription and improving the preparation process, the transdermal effect is improved, and the skin irritation is small, and the moisture retention performance and content stability of the ketoprofen gel are also significantly improved.
Description
技术领域Technical Field
本发明属于药物制剂技术领域,具体涉及一种酮洛芬凝胶剂及其制备方法。The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a ketoprofen gel and a preparation method thereof.
背景技术Background Art
公开该背景技术部分的信息仅仅旨在增加对本发明的总体背景的理解,而不必然被视为承认或以任何形式暗示该信息构成已经成为本领域一般技术人员所公知的现有技术。The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
酮洛芬是一种非甾体类抗炎镇痛药,也被称为布洛芬酮,功能主治包括:(1)镇痛作用:酮洛芬能够有效缓解轻至中度的疼痛,包括头痛、牙痛、关节痛、肌肉痛等,它通过抑制COX减少前列腺素的合成,其中包括前列腺素E2(PGE2),这种前列腺素可以使神经末梢敏感化,导致疼痛的发生,酮洛芬减少了前列腺素的合成,进而减轻了疼痛感;(2)抗炎作用:酮洛芬可减轻炎症引起的疼痛和不适,适用于关节炎、类风湿性关节炎等炎症性疾病,酮洛芬通过抑制环氧化酶(COX)的活性来发挥其抗炎作用,COX是一个关键的酶,参与了花生四烯酸(arachidonic acid)向前列腺素的转化过程,前列腺素是一类促炎介质,参与了炎症反应的发生,酮洛芬抑制COX的活性,减少了前列腺素的合成,从而减轻了炎症症状;(3)退烧作用:酮洛芬也具有降低体温的作用,适用于发热引起的不适,在发热过程中,白细胞释放前列腺素E2(PGE2),PGE2通过影响下丘脑温调中心而引起体温升高,酮洛芬通过抑制PGE2的合成,减少了PGE2对下丘脑温调中心的刺激,从而减轻了发热的症状。Ketoprofen is a nonsteroidal anti-inflammatory analgesic, also known as ibuprofen ketone. Its functions and indications include: (1) Analgesic effect: Ketoprofen can effectively relieve mild to moderate pain, including headache, toothache, joint pain, muscle pain, etc. It reduces the synthesis of prostaglandins, including prostaglandin E2 (PGE2), by inhibiting COX. This prostaglandin can sensitize nerve endings and cause pain. Ketoprofen reduces the synthesis of prostaglandins and thus reduces the pain. (2) Anti-inflammatory effect: Ketoprofen can relieve pain and discomfort caused by inflammation. It is suitable for inflammatory diseases such as arthritis and rheumatoid arthritis. Ketoprofen exerts its anti-inflammatory effect by inhibiting the activity of cyclooxygenase (COX). COX is a key enzyme involved in the synthesis of arachidonic acid (arachidonic acid). (3) Antipyretic effect: Ketoprofen also has the effect of lowering body temperature and is suitable for discomfort caused by fever. During fever, white blood cells release prostaglandin E2 (PGE2). PGE2 causes an increase in body temperature by affecting the hypothalamic temperature regulation center. Ketoprofen reduces the stimulation of PGE2 on the hypothalamic temperature regulation center by inhibiting the synthesis of PGE2, thereby alleviating the symptoms of fever.
经皮给药是一种通过皮肤无创的将药物运送到体内的途径。与传统的直接给药途径不同,经皮给药不需要使用针头注射,也不涉及通过胃肠道,小分子药物通常可利用细胞内途径来穿过表皮角质层,因此不会出现首过代谢而导致药物损失,并且药物可以在不受pH值、酶和肠道细菌干扰的情况下输送。Transdermal drug delivery is a non-invasive way to deliver drugs into the body through the skin. Unlike traditional direct drug delivery routes, transdermal drug delivery does not require the use of needle injections and does not involve passing through the gastrointestinal tract. Small molecule drugs can usually use intracellular pathways to pass through the epidermal stratum corneum, so there will be no first-pass metabolism that leads to drug loss, and drugs can be delivered without interference from pH, enzymes, and intestinal bacteria.
酮洛芬凝胶是一种局部外用药物,含有酮洛芬作为主要活性成分,通过涂抹、按摩直接作用于皮肤表面和局部组织,从而渗透皮肤并在炎症部位释放酮洛芬,用于局部治疗疼痛和炎症,具体可用于治疗关节炎、类风湿性关节炎等炎症性疾病。Ketoprofen gel is a topical medication that contains ketoprofen as the main active ingredient. It acts directly on the skin surface and local tissues through application and massage, thereby penetrating the skin and releasing ketoprofen at the site of inflammation. It is used for local treatment of pain and inflammation, and can be used specifically to treat inflammatory diseases such as arthritis and rheumatoid arthritis.
公开号为CN103156803A的中国专利公开了一种酮洛芬凝胶及其制备方法,由包括下述组分制备得到:酮洛芬2%~5%、基质材料0.5%~2%、透皮促进剂2%~4%、中和剂0.5%~5%、抗氧剂0.05%~0.2%、乙醇20%~50%,剩余为水。Chinese patent publication number CN103156803A discloses a ketoprofen gel and a preparation method thereof, which is prepared from the following components: 2% to 5% ketoprofen, 0.5% to 2% matrix material, 2% to 4% transdermal enhancer, 0.5% to 5% neutralizer, 0.05% to 0.2% antioxidant, 20% to 50% ethanol, and the remainder is water.
公开号为CN110693860A的中国专利公开了含酮洛芬的凝胶贴膏及其制备方法,其处方中包括了酮洛芬或其药用盐、水性高分子化合物、保湿剂、增稠剂等。Chinese patent publication number CN110693860A discloses a ketoprofen-containing gel patch and a preparation method thereof, wherein the prescription includes ketoprofen or a pharmaceutically acceptable salt thereof, an aqueous polymer compound, a moisturizer, a thickener, and the like.
现有技术酮洛芬凝胶均存在透皮效果不佳,主要成分易分解的缺陷,尤其是在光照下,更加不稳定。The existing ketoprofen gels all have the disadvantages of poor transdermal effect and easy decomposition of the main components, especially under light, making them more unstable.
发明内容Summary of the invention
克服现有技术的不足,本发明提供了一种透皮效果好、刺激性小、含量稳定、质量良好的酮洛芬凝胶剂。The present invention overcomes the deficiencies of the prior art and provides a ketoprofen gel with good transdermal effect, low irritation, stable content and good quality.
具体而言,本发明提供的酮洛芬凝胶剂由以下组分组成:酮洛芬2~4重量份、西黄蓍胶1~3重量份、硫代甘油0.5~1.5重量份、L-苯丙氨酸0.5~1重量份、丙三醇三乙酸酯1~5重量份、乙醇10~15重量份、抑菌剂0.01~0.2重量份、水。Specifically, the ketoprofen gel provided by the present invention is composed of the following components: 2 to 4 parts by weight of ketoprofen, 1 to 3 parts by weight of tragacanth gum, 0.5 to 1.5 parts by weight of thioglycerol, 0.5 to 1 parts by weight of L-phenylalanine, 1 to 5 parts by weight of glycerol triacetate, 10 to 15 parts by weight of ethanol, 0.01 to 0.2 parts by weight of an antibacterial agent, and water.
需要说明的是,抑菌剂在凝胶剂中起到保持产品无菌状态、预防交叉感染、延长产品使用寿命和增强产品安全性等作用,可以选自苯甲醇、三氯叔丁醇、羟苯乙酯、苯扎溴铵、羟苯丙酯、山梨酸、氯甲酚、羟丙甲酯、硝酸苯汞中的一种或多种,属于本领域技术人员的常规实验操作,确保在安全用量范围内即可。It should be noted that the antibacterial agent in the gel plays the role of maintaining the sterility of the product, preventing cross infection, extending the service life of the product and enhancing the safety of the product. It can be selected from one or more of benzyl alcohol, chlorobutanol, ethylparaben, benzalkonium bromide, propylparaben, sorbic acid, chlorocresol, hydroxypropylmethyl ester and phenylmercuric nitrate. It is a routine experimental operation for those skilled in the art to ensure that it is within the safe dosage range.
在其中一个实施例中,所述酮洛芬凝胶剂由以下组分组成:酮洛芬3重量份、西黄蓍胶2.5重量份、硫代甘油1重量份、L-苯丙氨酸0.7重量份、丙三醇三乙酸酯2.5重量份、乙醇12重量份、羟苯乙酯0.1重量份、水。In one embodiment, the ketoprofen gel is composed of the following components: 3 parts by weight of ketoprofen, 2.5 parts by weight of tragacanth gum, 1 part by weight of monothioglycerol, 0.7 parts by weight of L-phenylalanine, 2.5 parts by weight of glycerol triacetate, 12 parts by weight of ethanol, 0.1 parts by weight of ethylparaben, and water.
在其中一个实施例中,所述酮洛芬凝胶剂由以下组分组成:酮洛芬2重量份、西黄蓍胶2重量份、硫代甘油0.8重量份、L-苯丙氨酸0.8重量份、丙三醇三乙酸酯2重量份、乙醇13重量份、硝酸苯汞0.05重量份、水。In one embodiment, the ketoprofen gel is composed of the following components: 2 parts by weight of ketoprofen, 2 parts by weight of tragacanth gum, 0.8 parts by weight of thioglycerol, 0.8 parts by weight of L-phenylalanine, 2 parts by weight of glycerol triacetate, 13 parts by weight of ethanol, 0.05 parts by weight of phenylmercuric nitrate, and water.
根据药物用量与规格,所述酮洛芬凝胶的质量分数为2.0%~3.0%。According to the dosage and specifications of the medicine, the mass fraction of the ketoprofen gel is 2.0% to 3.0%.
为了提高酮洛芬凝胶的稳定性,本发明还提供了一种制备上述酮洛芬凝胶剂的方法:In order to improve the stability of ketoprofen gel, the present invention also provides a method for preparing the above ketoprofen gel:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为2.5~4.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于35℃~50℃水浴中保温4~8h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 2.5 to 4.5, stir, and keep warm in a water bath at 35° C. to 50° C. for 4 to 8 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入缓冲液调节pH为5.5~6.5,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding a buffer to adjust the pH to 5.5-6.5, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
其中,所述步骤(2)中的缓冲溶液选自碳酸盐缓冲液、磷酸盐缓冲液、柠檬酸盐缓冲液的至少一种,属于本领域技术人员的常规操作。The buffer solution in step (2) is selected from at least one of carbonate buffer, phosphate buffer and citrate buffer, which is a routine operation for those skilled in the art.
在其中一个实施例中,制备酮洛芬凝胶的方法步骤为:In one embodiment, the method for preparing ketoprofen gel comprises the following steps:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40°C for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。所述步骤(1)中pH为3.5。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the product. The pH in step (1) is 3.5.
与现有技术相比,本发明的技术效果在于:Compared with the prior art, the technical effects of the present invention are:
本发明酮洛芬凝胶剂通过优化处方、改进制备工艺,动物实验证明透皮效果好、刺激性小,加速试验中有效成分含量稳定。尤其是在处方中加入了一定用量范围的L-苯丙氨酸,有效稳定了活性成分酮洛芬,并且创新式的改进制备方法,通过两次调节pH,显著提升了酮洛芬凝胶的保湿性能和含量稳定性。The ketoprofen gel of the present invention has good transdermal effect and low irritation through optimized prescription and improved preparation process, and animal experiments prove that the active ingredient content is stable in accelerated tests. In particular, L-phenylalanine in a certain dosage range is added to the prescription to effectively stabilize the active ingredient ketoprofen, and the innovative improved preparation method significantly improves the moisture retention performance and content stability of the ketoprofen gel by adjusting pH twice.
附图说明BRIEF DESCRIPTION OF THE DRAWINGS
图1为实施例1~4、对比例1~6酮洛芬凝胶剂的有效成分累计渗透量。FIG. 1 shows the cumulative penetration of the active ingredients of the ketoprofen gels of Examples 1 to 4 and Comparative Examples 1 to 6.
图2为实施例1~4、对比例1~6酮洛芬凝胶剂的有效成分透皮吸收率。FIG. 2 shows the transdermal absorption rate of the active ingredient of ketoprofen gel of Examples 1 to 4 and Comparative Examples 1 to 6.
图3为实施例1~4、对比例1~6酮洛芬凝胶剂的皮肤滞留量。FIG3 shows the skin retention of ketoprofen gels of Examples 1 to 4 and Comparative Examples 1 to 6.
图4为A~H酮洛芬凝胶的失水情况。FIG. 4 shows the water loss of ketoprofen gels A to H.
图5为I~K组酮洛芬凝胶的失水情况。FIG5 shows the water loss of ketoprofen gel in groups I to K.
图6为A~K组酮洛芬凝胶加速试验含量变化图。FIG6 is a graph showing the changes in the content of ketoprofen gel in groups A to K in an accelerated test.
图7为L-苯丙氨酸对酮洛芬凝胶剂的有效成分含量的影响。FIG. 7 shows the effect of L-phenylalanine on the content of the active ingredient of ketoprofen gel.
具体实施方式DETAILED DESCRIPTION
为了使本发明的目的、技术方案更加清楚明白,以下结合实施例,对本发明做进一步的说明,但是本发明的保护范围并不限于这些实施例,实施例仅用于解释本发明。本领域技术人员应该理解的是,凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
实施例1酮洛芬凝胶剂Example 1 Ketoprofen gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40°C for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
实施例2酮洛芬凝胶剂Example 2 Ketoprofen gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40°C for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
实施例3酮洛芬凝胶剂Example 3 Ketoprofen gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为2.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于30℃水浴中保温4h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 2.5, stir, and keep in a water bath at 30° C. for 4 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入碳酸盐缓冲液调节pH为5.5,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding carbonate buffer to adjust the pH to 5.5, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
实施例4酮洛芬凝胶剂Embodiment 4 Ketoprofen gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为4.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于50℃水浴中保温8h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 4.5, stir, and keep in a water bath at 50°C for 8 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入磷酸盐缓冲液调节pH为6.5,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding phosphate buffer to adjust the pH to 6.5, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例1酮洛芬凝胶剂Comparative Example 1 Ketoprofen gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, and glycerol triacetate, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40° C. for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例2酮洛芬凝胶剂Comparative Example 2 Ketoprofen Gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、色氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and tryptophan, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40° C. for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例3酮洛芬凝胶剂Comparative Example 3 Ketoprofen Gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer with a pH of 3.5, stir, and keep in a water bath at 40°C for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例4酮洛芬凝胶剂Comparative Example 4 Ketoprofen Gel
配方:formula:
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,搅拌,于40℃水浴中保温6h,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount of swelling agent, stir, and keep in a water bath at 40° C. for 6 hours to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例5酮洛芬凝胶剂Comparative Example 5 Ketoprofen Gel
加水至100mlAdd water to 100ml
制备方法:Preparation method:
(1)将西黄蓍胶、硫代甘油、丙三醇三乙酸酯、L-苯丙氨酸混合,加入适量溶胀,加入pH为3.5的磷酸氢二钠-柠檬酸缓冲液,搅拌,得到胶质中间物;(1) Mix tragacanth gum, thioglycerol, glycerol triacetate, and L-phenylalanine, add an appropriate amount to swell, add disodium hydrogen phosphate-citric acid buffer solution with a pH of 3.5, and stir to obtain a colloid intermediate;
(2)向胶质中间物中加入乙醇进行稀释,冷却至常温,并加入柠檬酸盐缓冲液调节pH为5.0,加入防腐剂,得到凝胶基质;(2) adding ethanol to the colloid intermediate to dilute it, cooling it to room temperature, adding citrate buffer to adjust the pH to 5.0, and adding a preservative to obtain a gel matrix;
(3)向凝胶基质中加入酮洛芬,搅拌均匀,即得。(3) Add ketoprofen to the gel matrix and stir evenly to obtain the gel matrix.
对比例6市售酮洛芬凝胶(批准文号H20150425)Comparative Example 6 Commercially available ketoprofen gel (approval number H20150425)
酮洛芬凝胶的经皮渗透性实验Transdermal permeation experiment of ketoprofen gel
实验动物Experimental animals
SD大鼠,SPF级,180-220g,实验动物许可证号:SYXK(鲁)20180008,实验前适应性饲养一周。SD rats, SPF grade, 180-220 g, experimental animal license number: SYXK(Lu)20180008, were adaptively raised for one week before the experiment.
实验步骤:利用8%硫化钠溶液对大鼠进行脱毛,饲养24h,处死,取腹部皮肤,去除皮下脂肪,用生理盐水洗净,滤纸吸去表面水分,皮肤固定于接受池与供给池之间,供给池分别精密量取等体积的实施例1~5酮洛芬凝胶剂、对比实施例6酮洛芬凝胶剂,均匀涂抹于皮肤上,涂抹面积、时间相同,确保实验的一致性,皮肤角质层朝上,接受池内生理盐水为接受液,且接受液与皮肤真皮层刚好接触,置于(37±0.5)℃恒温水浴中,以200r/min的转速搅拌。分别于2、4、8、12、24h取样5mL,同时补充等体积的生理盐水。取出的接受液微孔滤膜过滤,进样20μL,记录峰面积,计算酮洛芬浓度,并计算累积渗透量(Q),以酮洛芬的累积渗透量为指标,通过透皮吸收试验研究酮洛芬凝胶的透皮吸收率。Experimental procedure: 8% sodium sulfide solution was used to depilate rats, and the rats were fed for 24 hours and then killed. The abdominal skin was taken, subcutaneous fat was removed, and the rats were washed with physiological saline. The surface moisture was removed by filter paper. The skin was fixed between the receiving pool and the supply pool. The supply pool was precisely measured with equal volumes of ketoprofen gels of Examples 1 to 5 and ketoprofen gels of Comparative Example 6, and evenly applied to the skin. The application area and time were the same to ensure the consistency of the experiment. The stratum corneum of the skin was facing upward, and the physiological saline in the receiving pool was the receiving solution, and the receiving solution just contacted the dermis of the skin, and the rats were placed in a (37±0.5)°C constant temperature water bath and stirred at a speed of 200r/min. 5mL samples were taken at 2, 4, 8, 12, and 24h, and an equal volume of physiological saline was added at the same time. The taken out receiving solution was filtered through a microporous filter membrane, 20 μL of the sample was injected, the peak area was recorded, the ketoprofen concentration was calculated, and the cumulative permeation amount (Q) was calculated. The cumulative permeation amount of ketoprofen was used as an indicator to study the transdermal absorption rate of ketoprofen gel through a transdermal absorption test.
其中V为接受液总体积,Cn为第n个取样点测得的药物浓度(μg/mL),C为第i个取样点测得的药物浓度(μg/mL),V为取样体积,A为扩散渗透面积(cm2)。Where V is the total volume of the receiving solution, Cn is the drug concentration measured at the nth sampling point (μg/mL), C is the drug concentration measured at the ith sampling point (μg/mL), V is the sampling volume, and A is the diffusion permeation area (cm 2 ).
体外透皮试验结束后,取出大鼠皮肤,洗涤表面,擦干,剪碎,加pH=7.4磷酸缓冲液5mL,匀浆,5000r·min-1离心5min,取上清液,用0.22μm滤膜过滤,取滤液,采用高效液相色谱法测定皮肤中酮洛芬的含量,测定酮洛芬凝胶的皮肤滞留量。After the in vitro permeation test, the rat skin was removed, the surface was washed, dried, cut into pieces, 5 mL of pH 7.4 phosphate buffer was added, homogenized, centrifuged at 5000 r·min-1 for 5 min, the supernatant was taken, filtered with a 0.22 μm filter membrane, and the filtrate was taken and the ketoprofen content in the skin was determined by high performance liquid chromatography, and the skin retention of ketoprofen gel was determined.
图1为实施例1~4、对比例1~6酮洛芬凝胶剂的有效成分累计渗透量。图2为实施例1~4、对比例1~6酮洛芬凝胶剂的有效成分透皮吸收率。图3为实施例1~4、对比例1~6酮洛芬凝胶剂的皮肤滞留量。实验结果显示,本发明实施例1~4酮洛芬凝胶剂可以提高活性成分酮洛芬的透皮效率,增加药物在目标组织中的浓度,增加活性成分在皮肤的滞留量,更有利于其在皮肤及其深层组织持续发挥良好的治疗作用,提高治疗效果。Figure 1 shows the cumulative penetration of the active ingredients of the ketoprofen gels of Examples 1 to 4 and Comparative Examples 1 to 6. Figure 2 shows the transdermal absorption rate of the active ingredients of the ketoprofen gels of Examples 1 to 4 and Comparative Examples 1 to 6. Figure 3 shows the skin retention of the ketoprofen gels of Examples 1 to 4 and Comparative Examples 1 to 6. The experimental results show that the ketoprofen gels of Examples 1 to 4 of the present invention can improve the transdermal efficiency of the active ingredient ketoprofen, increase the concentration of the drug in the target tissue, increase the retention of the active ingredient in the skin, and are more conducive to its continued good therapeutic effect in the skin and its deep tissues, thereby improving the therapeutic effect.
酮洛芬凝胶剂刺激性试验Irritation test of ketoprofen gel
实验动物:SD大鼠,SPF级,180-220g,实验动物许可证号:SYXK(鲁)20180008,实验前适应性饲养一周。皮肤刺激性试验方法:取大鼠随机分为阴性对照组、实施例1~5酮洛芬凝胶剂、对比实施例6酮洛芬凝胶剂,每组10只,试验前24小时在背部中间褪毛,褪毛范围每只约5cm×5cm。给药前检查去毛皮肤无损伤者进行试验。将各组药物分别涂敷于脱毛皮肤上,连续涂敷给药8小时,在自然光线下观察皮肤反应,以皮肤是否红肿为考察指标,观察给药后0.5h、1h、6h、12h、24h、48h、72h的皮肤局部反应情况。结果如下:Experimental animals: SD rats, SPF grade, 180-220g, experimental animal license number: SYXK(Lu)20180008, adaptive feeding for one week before the experiment. Skin irritation test method: Rats were randomly divided into a negative control group, ketoprofen gel of Examples 1 to 5, and ketoprofen gel of comparative example 6, with 10 rats in each group. Hair was removed in the middle of the back 24 hours before the test, and the hair removal range was about 5cm×5cm for each rat. Before administration, the depilated skin was checked for damage and tested. Each group of drugs was applied to the depilated skin, applied continuously for 8 hours, and the skin reaction was observed under natural light. Whether the skin was red and swollen was used as the investigation index, and the local skin reaction was observed 0.5h, 1h, 6h, 12h, 24h, 48h, and 72h after administration. The results are as follows:
表1酮洛芬凝胶剂皮肤刺激试验Table 1 Ketoprofen gel skin irritation test
结果显示,本发明实施例1~5酮洛芬凝胶剂涂敷给药未见红斑和水肿,对皮肤刺激性小,具有市场应用价值。The results showed that the ketoprofen gels of Examples 1 to 5 of the present invention did not cause erythema and edema after application, had little irritation to the skin, and had market application value.
本发明酮洛芬凝胶剂制备方法实验探究Experimental study on the preparation method of ketoprofen gel of the present invention
处方与制备方法中的其他参数同实施例1,以下是各组变量:The other parameters in the prescription and preparation method are the same as those in Example 1. The following are the variables in each group:
A组:步骤(1)中加入pH为2.2的磷酸氢二钠-柠檬酸缓冲液Group A: Add sodium hydrogen phosphate-citric acid buffer with a pH of 2.2 in step (1)
B组:步骤(1)中加入pH为2.5的磷酸氢二钠-柠檬酸缓冲液Group B: Add sodium hydrogen phosphate-citric acid buffer with a pH of 2.5 in step (1)
C组:步骤(1)中加入pH为3.0的磷酸氢二钠-柠檬酸缓冲液Group C: Add sodium hydrogen phosphate-citric acid buffer with a pH of 3.0 in step (1)
D组:步骤(1)中加入pH为4.0的磷酸氢二钠-柠檬酸缓冲液Group D: Add sodium hydrogen phosphate-citric acid buffer with a pH of 4.0 in step (1)
E组:步骤(1)中加入pH为4.5的磷酸氢二钠-柠檬酸缓冲液Group E: Add sodium hydrogen phosphate-citric acid buffer with a pH of 4.5 in step (1)
F组:步骤(1)中加入pH为5.0的磷酸氢二钠-柠檬酸缓冲液Group F: Add sodium hydrogen phosphate-citric acid buffer with a pH of 5.0 in step (1)
G组:步骤(1)中加入pH为5.5的磷酸氢二钠-柠檬酸缓冲液Group G: Add sodium hydrogen phosphate-citric acid buffer with a pH of 5.5 in step (1)
H组:步骤(1)中加入pH为6.0的磷酸氢二钠-柠檬酸缓冲液Group H: Add sodium hydrogen phosphate-citric acid buffer with a pH of 6.0 in step (1)
I组:同实施例4Group I: Same as Example 4
J组:同实施例5Group J: Same as Example 5
K组:步骤(1)中水浴温度为60℃Group K: The water bath temperature in step (1) was 60°C
将上述A~H组制备所得的酮洛芬凝胶分别置于烘箱(30±1)℃、室温(23±1)℃、冰箱(5±1)℃中贮存7天,在实验前后进行称重,计算失水率,判断酮洛芬凝胶的失水情况。图4为A~H酮洛芬凝胶的失水情况,图5为I~K组酮洛芬凝胶的失水情况。分析可知,制备方法中的第一次pH调节以及保温措施对酮洛芬凝胶的保湿稳定性均有影响。The ketoprofen gel prepared in groups A to H was placed in an oven at (30±1)°C, room temperature at (23±1)°C, and refrigerator at (5±1)°C for 7 days, and weighed before and after the experiment to calculate the water loss rate and determine the water loss of the ketoprofen gel. Figure 4 shows the water loss of ketoprofen gels in groups A to H, and Figure 5 shows the water loss of ketoprofen gels in groups I to K. Analysis shows that the first pH adjustment and heat preservation measures in the preparation method have an impact on the moisture retention stability of ketoprofen gel.
将上述A~K组制备所得的酮洛芬凝胶按市售包装,于温度40℃±2℃,相对湿度75%±5%的条件下进行加速试验,分别于第1天、第2个月末、第3个月末、第6个月末取样检测酮洛芬含量。照《中国药典》高效液相色谱法(通则0512)测定。供试品溶液:精密量取本品适量,用流动相定量稀释制成每1ml中约含酮洛芬0.1mg的溶液。对照品溶液:取酮洛芬对照品适量,精密称定,加流动相溶解并定量稀释制成每1ml中约含0.1mg的溶液。色谱条件:用十八烷基硅烷键合硅胶为填充剂;以磷酸盐缓冲液(取磷酸二氢钾6.8g,加水溶解并稀释至100ml,用磷酸调节pH值至3.5+0.1)-乙腈-水(2:43:55)为流动相;检测波长为255nm;进样体积10μl。系统适用性要求:理论板数按酮洛芬峰计算不低于2000。测定法:精密量取供试品溶液与对照品溶液,分别注入液相色谱仪,记录色谱图。按外标法以峰面积计算。图6为A~K组酮洛芬凝胶加速试验含量变化图。The ketoprofen gel prepared by the above-mentioned groups A to K was packaged in commercial packaging and subjected to an accelerated test at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5%. The ketoprofen content was tested by sampling at the first day, the end of the second month, the end of the third month, and the end of the sixth month. The test was performed according to the high performance liquid chromatography method (General Rule 0512) of the Chinese Pharmacopoeia. Test solution: Accurately measure an appropriate amount of this product and quantitatively dilute it with the mobile phase to prepare a solution containing about 0.1 mg of ketoprofen per 1 ml. Reference solution: Take an appropriate amount of ketoprofen reference substance, accurately weigh it, dissolve it in the mobile phase, and quantitatively dilute it to prepare a solution containing about 0.1 mg per 1 ml. Chromatographic conditions: octadecylsilane bonded silica gel is used as filler; phosphate buffer (take 6.8g of potassium dihydrogen phosphate, dissolve in water and dilute to 100ml, adjust the pH value to 3.5+0.1 with phosphoric acid)-acetonitrile-water (2:43:55) is used as mobile phase; detection wavelength is 255nm; injection volume is 10μl. System suitability requirements: The number of theoretical plates calculated based on the ketoprofen peak is not less than 2000. Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, and record the chromatogram. Calculate by peak area according to the external standard method. Figure 6 is a graph showing the content change of ketoprofen gel accelerated test in groups A to K.
需要说明的是,实施例1~4酮洛芬凝胶剂的失水情况实验和加速实验有效成分含量变化实验的结果与B~E组实验结果类似,均具有很好的稳定性,失水率低,含量稳定性高。下面仅列举部分实验数据:It should be noted that the results of the water loss test and the accelerated test of the effective ingredient content change test of the ketoprofen gel in Examples 1 to 4 are similar to the experimental results of Groups B to E, and all have good stability, low water loss rate, and high content stability. Only some experimental data are listed below:
图7为实施例1、对比例1、对比例2酮洛芬凝胶的加速试验有效成分含量变化图。说明L-苯丙氨酸的适量加入能够对酮洛芬起到稳定作用。Figure 7 is a graph showing the changes in the effective ingredient content of ketoprofen gel in the accelerated test of Example 1, Comparative Example 1 and Comparative Example 2, indicating that the addition of an appropriate amount of L-phenylalanine can stabilize ketoprofen.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410445904.9A CN118526444B (en) | 2024-04-15 | 2024-04-15 | A kind of ketoprofen gel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410445904.9A CN118526444B (en) | 2024-04-15 | 2024-04-15 | A kind of ketoprofen gel and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118526444A true CN118526444A (en) | 2024-08-23 |
CN118526444B CN118526444B (en) | 2025-02-28 |
Family
ID=92385255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410445904.9A Active CN118526444B (en) | 2024-04-15 | 2024-04-15 | A kind of ketoprofen gel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118526444B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525875A (en) * | 2010-12-21 | 2012-07-04 | 重庆医药工业研究院有限责任公司 | Loxoprofen sodium gel |
CN103156803A (en) * | 2011-12-08 | 2013-06-19 | 杭州赛利药物研究所有限公司 | Ketoprofen gel and preparation method thereof |
RU2013119202A (en) * | 2013-04-25 | 2014-10-27 | Закрытое Акционерное Общество "Фармфирма "Сотекс" | TRANSDERMAL AGENT FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES, METHOD FOR ITS PRODUCTION AND COMBINED TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF HEADS AND MYTH |
CN104337757A (en) * | 2014-10-10 | 2015-02-11 | 辽宁大学 | Ketoprofen transdermal nanocrystalline gel and preparation method thereof |
-
2024
- 2024-04-15 CN CN202410445904.9A patent/CN118526444B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525875A (en) * | 2010-12-21 | 2012-07-04 | 重庆医药工业研究院有限责任公司 | Loxoprofen sodium gel |
CN103156803A (en) * | 2011-12-08 | 2013-06-19 | 杭州赛利药物研究所有限公司 | Ketoprofen gel and preparation method thereof |
RU2013119202A (en) * | 2013-04-25 | 2014-10-27 | Закрытое Акционерное Общество "Фармфирма "Сотекс" | TRANSDERMAL AGENT FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES, METHOD FOR ITS PRODUCTION AND COMBINED TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF HEADS AND MYTH |
CN104337757A (en) * | 2014-10-10 | 2015-02-11 | 辽宁大学 | Ketoprofen transdermal nanocrystalline gel and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN118526444B (en) | 2025-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001284191C1 (en) | Transdermal pharmaceutical delivery composition | |
US5093133A (en) | Method for percutaneous delivery of ibuprofen using hydroalcoholic gel | |
JP6434104B2 (en) | Diclofenac formulation | |
EP0104037B1 (en) | Antiinflammatory and analgesic gel | |
CN106138129A (en) | A kind of Chinese medicine compound thermosensitive hydrogel agent treating oral ulcer disease | |
WO2020093956A1 (en) | External preparation containing vitamin k1 and preparation method therefor | |
US4525348A (en) | Pranoprofen gelled ointment | |
CN101455654A (en) | Arginine ibuprofen gel and preparation method thereof | |
CN113491681A (en) | Application of cannabinoid molecule CBG in preparation of inflammatory pain medicines and medicinal preparation | |
JPH04193826A (en) | Sodium dichlofenac-containing percutaneous absorption type antiinflammatory-analgesic patch | |
CN108703946A (en) | A kind of transdermal absorption formulation for treating diabete peripheral herve pain | |
CN118526444A (en) | Ketoprofen gel and preparation method thereof | |
CN101618030B (en) | Triptolide transdermal patch and preparation method thereof | |
CN110559258A (en) | Tetrahydroberberine gel, preparation method thereof and transdermal rate detection method | |
CN101785753B (en) | Gastrodia elata genin transdermal gel for central nervous system disease treatment | |
CN113018254A (en) | Ibuprofen liquid crystal gel transdermal preparation for treating primary dysmenorrhea and preparation method thereof | |
CN108969525B (en) | Composition and method for treating postherpetic neuralgia | |
JP2764261B2 (en) | External anti-inflammatory analgesic | |
CN108969524B (en) | Method for treating postherpetic neuralgia | |
JPS63107916A (en) | External preparations of catecholamines | |
WO2025077886A1 (en) | Compound and method for treating and/or preventing actinic keratosis | |
CN113262216A (en) | External preparation for eliminating skin surface red swelling and easing pain | |
AU2010282099B2 (en) | Pharmaceutical solution of cetirizine hydrochloride | |
EP0143109A1 (en) | Pranoprofen gelled ointment | |
CN119318629A (en) | High-permeability diclofenac sodium liniment and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: No. 85, Gehu East Road, Wujin District, Changzhou City, Jiangsu Province 213100 Applicant after: Changzhou Wujin People's Hospital (Changzhou Eighth People's Hospital) Applicant after: JINAN SHUNJING PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: Room 2-1401, Building 5, Shunjing Garden, No. 6 Tianjiazhuang East Road, Tianqiao District, Jinan City, Shandong Province, 250000 Applicant before: JINAN SHUNJING PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Country or region before: China Applicant before: Changzhou Wujin People's Hospital (Changzhou Eighth People's Hospital) |
|
GR01 | Patent grant | ||
GR01 | Patent grant |